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TLR3 and TLR4 utilize adaptor TRIF to activate interferon regulatory factor 3 (IRF3), resulting in
interferon b (IFN-b) production to mediate anti-viral infection. In this report, we analyzed the effect
of two known phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin on LPS-
and poly(I:C)-induced IFN-b production in peritoneal macrophages. LY294002 inhibited LPS- and
poly(I:C)-induced IFN-b transcription and secretion. In contrast, wortmannin could not inhibit
IFN-b production. Furthermore, IRF3 transcriptional activation and binding to IFN-b promoter were
found to be inhibited by LY294002. Therefore, our ﬁndings demonstrate LY294002 negatively regu-
lates LPS- and poly(I:C)-induced IFN-b production through inhibition of IRF3 activation in a PI3K-
independent manner.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Phosphatidylinositol 3-kinase (PI3K) plays very important rolesToll-like receptors (TLRs) play a pivotal role in defense against
invading pathogens through the detection of pathogen-associated
molecular patterns (PAMPs) [1]. Recognition of PAMPs by TLRs initi-
ates complicated signaling pathways leading to the production of pro-
inﬂammatory cytokines and type I interferons [2,3]. TLR3 and TLR4
recruits Toll/IL-1R (TIR) domain-containing adaptor-inducing IFN-b
(TRIF) and promotes activation of NF-jB-activating kinase (NAK, also
known as TBK1)/IjB kinase (IKK) e, leading to the phosphorylation,
dimerization and nuclear translocation of IFN regulatory factor (IRF)
3 and the induction of interferon b (IFN-b) [3,4]. Although type I IFNs
are essential for the establishment of an anti-viral state, uncontrolled
expression of type I IFNs hasmanifested in diverse pathogenic autoim-
mune diseases, including systemic lupus erythematosus (SLE) [5,6].
Thus, understanding themechanisms that limit or down-regulate type
I IFNs production downstream of pathogen recognition is critical for
developing treatments for these diseases.chemical Societies. Published by E
; TLR, toll-like receptor; IRF3,
Immunology, Shandong Uni-
dong 250012, China. Fax: +86in cell survival, growth, proliferation, and other cellular processes.
Recent studies have provided evidences for the involvement of
PI3K in TLR signaling [7]. In the PI3K-dependent signaling pathway,
phosphatidylinositol 3,4,5-triphosphate (PIP3) generated by PI3K
activates AKT,which is responsible formany of the biological conse-
quences of PI3K activation [8]. LY294002 and wortmannin are two
commonly used pharmacological inhibitors to investigate the effect
of PI3K in cellular responses. But, a number of conﬂicting results
have been reported using LY294002 and wortmannin [9,10]. In
these cases, LY294002 has been demonstrated to exert its function
through a PI3K-independent mechanism. LY294002 and wortman-
nin are two structurally distinct compounds. LY294002 is a syn-
thetic compound designed as a PI3K inhibitor based on the
ﬂavonoid quercetin [11]. Wortmannin as a speciﬁc PI3K inhibitor
was originally isolated from Penicillium wortmannii [12]. Unlike
wortmannin, LY294002 has been reported to directly bind and inhi-
bit other kinases and non-kinase proteins in addition to PI3K [13].
Therefore, usage of LY294002 to study the function of PI3K and
explanation the results should be careful.
In this study, the effect of LY294002 and wortmannin on LPS-
and poly(I:C)-induced IFN-b production in peritoneal primary
macrophages was analyzed. We found LY294002 inhibited LPS
and poly(I:C)-induced IFN-b transcription and secretion in a
PI3K-independent manner. In contrast, wortmannin did not have
this inhibitory effect. Furthermore, our data demonstrated
LY294002 inhibited IFN-b production via suppression of interferon
regulatory factor 3 (IRF3) activation.lsevier B.V. All rights reserved.
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2.1. Mice and reagent
C57BL/6J mice were obtained from Joint Ventures Sipper BK
Experimental Animal (Shanghai, China). All animal experiments
were undertaken in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals, with
the approval of the Scientiﬁc Investigation Board of Medical
School of Shandong University, Jinan, China. LPS (Escherichia coli,
055:B5) and poly(I:C) were purchased from Sigma (St. Louis,
MO). LY294002, LY303511 and wortmannin were purchased from
Calbiochem (San Diego, CA). Antibodies for phosphorylated AKT
(Ser473) and AKT were from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies for IRF3 were from Cell Signaling (Cell Sig-
naling, MA). ELISA kits for murine IFN-b was purchased from R&D
Systems. (Minneapolis, MN). IFN-b/IRF3 reporter plasmids and
TRIF/TBK1 expression plasmids were kind gifts from Dr. Xuetao
Cao [14].2.2. Cell culture
HEK293-TLR3 cell line was obtained from Invivogen (San Diego,
CA, USA). Mouse primary peritoneal macrophages were prepared as
described [15]. The cells were cultured at 37 C under 5% CO2 in
DMEM supplemented with 10% FCS (Invitrogen-Gibco), 100 U/ml
penicillin, and 100 lg/ml streptomycin. LPS and poly(I:C)were used
at a ﬁnal concentration of 100 ng/ml and 20 lg/ml, respectively.2.3. RNA quantiﬁcation
Total RNA was extracted with TRIzol reagent according to the
manufacturer’s instructions (Invitrogen) as described previously
[15]. The sequences of primers were 50-ATGAGTGGTGGTTGCAGG
C-30(sense), 50-TGACCTTTCAAATGCAGTAGATTCA-30 (antisense)
for IFN-b and 50-TGTTACCAACTGGGACGACA-30(sense), 50-CTGGG
TCATCTTTTCACGGT-30 (antisense) for b-actin.2.4. Assay of luciferase reporter gene expression
HEK293-TLR3 cells were cotransfected with indicated luciferase
reporter plasmid and pRL-TK-Renilla-luciferase plasmid using Jet-
PEI transfection reagent (Polyplus). After 24 h, the cells were left
untreated or treated with poly(I:C). Luciferase activities were mea-
sured with Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions. Data are normalized
for transfection efﬁciency by dividing Fireﬂy luciferase activity
with that of Renilla luciferase.Fig. 1. LPS-induced PI3K activation is inhibited by LY294002 and wortmannin. (A)
Mouse peritoneal macrophages were pretreated with DMSO, 25 lM LY294002,
25 lM LY303511 or 1 lMwortmannin for 40 min and then stimulated with 100 ng/
ml LPS for 1 h. PI3K activation was analyzed by western blot analysis of
phosphorylated Akt in the whole cell lysates. Similar results were obtained in
three independent experiments. (B) The levels of Akt activation were quantiﬁed by
measuring band intensities and shown as fold increase relative to total Akt.2.5. Electrophoretic mobility shift assays (EMSA)
EMSA experiments were performed as described previously
[16]. Brieﬂy, 1  106 mouse peritoneal macrophages were seeded
into 6-well plates and incubated overnight. Cells were treated
with DMSO, LY294002, LY303511, or wortmannin for 40 min,
and stimulated with LPS for 1 h. Nuclear extracts were prepared
with NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce, Rockford, IL). Synthetic complementary oligonucleotides
were 30-biotinylated using the biotin 30-end DNA labeling kit
(Pierce, Rockford, IL) according to the manufacturer’s instructions
and annealed for 2 h at room temperature. The sequence of the
oligonucleotides used is 5-GAAAACTGAAAGGGAGAACTGAAA-30
(nt 142 to nt 119) from the mouse IFN-b promoter.2.6. Statistical analysis
All data are presented as means ± S.D. of three or four experi-
ments. Analysis was performed using a Student’s t-test. Values of
p < 0.05 were considered signiﬁcant.
3. Results
3.1. LY294002 inhibits TLR3/4-induced IFN-b production
in a PI3K-independent manner
In order to investigate the possible functions of PI3K on TLR3/4-
induced IFN-b production, primary peritoneal macrophages were
pretreated with known PI3K inhibitors wortmannin and
LY294002, followed by stimulation with LPS or poly(I:C). First,
the inhibitory effect of PI3K inhibitors was examined by western
blot analysis using phosphospeciﬁc antibody against Akt, a well-
known downstream target of PI3K. As shown in Fig. 1, Akt phos-
phorylation was greatly increased with LPS stimulation, indicating
LPS could induce PI3K activation as reported previously [10]. Treat-
ment with both wortmannin and LY294002 greatly attenuated
LPS-induced Akt phosphorylation. In contrast, LPS-induced Akt
phosphorylation could not be inhibited by LY303511, an inactive
analogue of LY294002. These data indicated that wortmannin
and LY294002 could sufﬁciently inhibit LPS-induced PI3K activa-
tion in primary macrophages.
Next, the effect of PI3K inhibitors on LPS- and poly(I:C)-induced
IFN-b expression was investigated (Fig. 2). Both LPS and poly(I:C)
could increase the levels of IFN-b steady state mRNA after stimula-
tion for 2 and 4 h. Such an increase was inhibited by the treatment
with LY294002 and LY303511. In contrast, wortmannin could
not decrease LPS- and poly(I:C)-induced IFN-b steady state mRNA.
Similarly, LPS- and poly(I:C)-induced secretion of IFN-b was
also greatly attenuated by LY294002, but not by wortmannin. In
the case of LPS stimulation, wortmannin greatly enhanced the
Fig. 2. LY294002 inhibits TLR3/4-induced IFN-b production in a PI3K-independent manner. (A) Mouse peritoneal macrophages were pretreated with DMSO, 25 lM
LY294002, 25 lM LY303511 or 1 lMwortmannin for 40 min and then stimulated with 100 ng/ml LPS or 20 lg/ml poly(I:C) for 2 h and 4 h. Steady state mRNA level of IFN-b
was examined by RT-PCR. Similar results were obtained in three independent experiments. (B) Mouse peritoneal macrophages were pretreated with DMSO, 25 lM LY294002
or 1 lM wortmannin for 40 min and then stimulated with 100 ng/ml LPS or 20 lg/ml poly(I:C) for 8 h. The secretion of IFN-b protein was detected by ELISA. Data are
representative of three independent experiments with similar results (mean ± S.D. of triplicate samples) (⁄⁄p < 0.01).
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wortmannin play different roles in the regulation of LPS- and
poly(I:C)-induced IFN-b production in primary macrophages.
Given the facts that wortmannin did not inhibit IFN-b secretion
and IFN-b mRNA expression and LY303511 inhibited IFN-b mRNA
expression, these data also suggest that LY294002 may inhibit
IFN-b expression in a PI3K-independent manner.
3.2. LY294002 inhibits TLR3/4-induced IFN-b expression
in a dose-dependent manner
In order to further conﬁrm LY294002-mediated inhibition of
LPS- and poly(I:C)-induced IFN-b expression, the primary macro-
phages were pretreated with increasing concentrations of
LY294002, then stimulated with LPS or poly(I:C). As shown in
Fig. 3A, the concentration as low as 5 lM could signiﬁcantly inhibit
LPS- and poly(I:C)-induced IFN-b mRNA expression. Importantly,
LPS- and poly(I:C)-induced IFN-b mRNA expression was further
inhibited with increasing concentrations of LY294002 (Fig. 3A).
Similarly, LPS- and poly(I:C)-induced IFN-b secretion was also
inhibited with LY294002 stimulation in a dose-dependent manner
(Fig. 3B).
To investigate the function of LY294002 on the inhibition of
IFN-b expression at the transcriptional level, IFN-b promoter lucif-
erase reporter was transfected into HEK293 cells stably expressing
TLR3. As shown in Fig. 3C, stimulation with poly(I:C) greatly in-
creased the luciferase activity. Treatment with LY294002 signiﬁ-
cantly attenuated poly(I:C)-induced luciferase activation in a
dose-dependent manner. Similarly, LY303511 also inhibited
poly(I:C)-induced luciferase activation in a dose-dependent
manner. In sharp contrast, wortmannin could not inhibit
poly(I:C)-induced luciferase activity. All together, these data indi-
cate that LY294002 inhibits LPS- and poly(I:C)-induced IFN-b
mRNA expression and protein secretion in primary macrophages
at the transcriptional level.
3.3. LY29400 targets molecules downstream of TBK1
TLR3 and TLR4 initiate the TRIF-dependent pathway that in-
volves TBK1 to phosphorylate IRF3, resulting in IRF3 dimerization
and subsequent nuclear translocation to regulate IFN-b transcrip-tion [2,3]. Transfection of TRIF and TBK1 expression plasmid can
lead to IFN-b transcription in HEK293 cells. To determine the
molecular targets of LY294002 in TLR3/4-induced IFN-b produc-
tion, the effects of LY294002 on IFN-b promoter activation medi-
ated by TRIF and TBK1 were examined in reporter assays. As
shown in Fig. 4A, TRIF transfection greatly increased IFN-b pro-
moter activation in HEK293 cells. Treatment of LY294002 or
LY303511 signiﬁcantly inhibited TRIF-induced IFN-b promoter
activation in a dose-dependent manner. Similarly, TBK1-induced
IFN-b promoter activation was also inhibited with the treatment
of LY294002 or LY303511 in a dose-dependent manner (Fig. 4B).
These data suggest that LY294002 targets molecules downstream
of TBK1 to inhibit TLR3/4-induced IFN-b production.
3.4. LY294002 inhibits IRF3 transcriptional activation
and binding to IFN-b promoter
IRF3 activation is required for IFN-b production in TLR3/4 sig-
naling pathway. In order to investigate the function of LY294002
on IRF3 transcriptional activation, an IRF3 cis-reporting plasmid
was transfected into HEK293 cells stably expressing TLR3. As
shown in Fig. 5A, poly(I:C) stimulation greatly increased IRF3 tran-
scriptional activation. After treatment with LY294002 and
LY303511, poly(I:C)-induced IRF3 transcriptional activation was
decreased in a dose-dependent manner. These data indicate that
LY294002 inhibits poly(I:C) induced IRF3 transcriptional activity.
Activation of IRF3 results in binding to PRDIII-I of the IFN-b pro-
moter. To investigate the effect of LY294002 on IRF3 binding IFN-b
promoter, EMSA was performed using a biotin-labeled 24-nt frag-
ment (nt 142 to 119) containing the PRDIII-I of the IFN-b pro-
moter. Nuclear protein was isolated from control and poly(I:C)-
treated primary macrophages in the presence of LY294002,
LY303511 or wortmannin. As shown in Fig. 5B, nuclear proteins
from poly(I:C)-stimulated cells were bound to the labeled probe.
In contrast, this binding was greatly decreased with nuclear pro-
teins from poly(I:C)-stimulated cells pretreated with LY294002
and LY303511. Consistent with the expression data and luciferase
data, wortmannin could not inhibit IRF3 binding to IFN-b pro-
moter. Unlabeled nonspeciﬁc probes could not compete IRF3 bind-
ing, in contrast, unlabeled speciﬁc probes competed the IRF3
binding (Fig. 5C). Importantly, IRF3 antibody also disrupted the
Fig. 3. LY294002 inhibits TLR3/4-induced IFN-b expression in a dose-dependent manner. (A) Mouse peritoneal macrophages were pretreated with DMSO, or LY294002 (5, 15,
30 lM) for 40 min and then stimulated with 100 ng/ml LPS or 20 lg/ml poly(I:C) for 4 h. Expression level of IFN-b mRNA was examined by RT-PCR. Similar results were
obtained in three independent experiments. (B) Mouse peritoneal macrophages were treated as in panel A, the secretion of IFN-b protein was detected by ELISA. Data are
representative of three independent experiments with similar results (mean ± SD of triplicate samples) (⁄⁄p < 0.01). (C) HEK293-TLR3 cells in 96-well plates (3  104/well)
were transiently transfected with 100 ng IFN-b reporter plasmid and 10 ng pTK-Renilla plasmid. After 24 h, cells were pretreated with DMSO, 25 lM LY294002, 25 lM
LY303511 or 1 lMwortmannin and then stimulated with 20 lg/ml poly(I:C) for 6 h. Luciferase activity was measured and normalized by Renilla luciferase activity. Data are
shown as mean ± SD (n = 6) of one representative experiment (⁄⁄p < 0.01).
Fig. 4. LY29400 targets molecules downstream of TBK1. (A and B) HEK293 cells in 96-well plates (3  104/well) were transiently with TRIF or TBK1 expression plasmid, along
with IFN-b reporter plasmid and pTK-Renilla plasmid. After 8 h of culture, cells were treated with DMSO, 25 lM LY294002 or 25 lM LY303511 and then cultured for 16 h.
Luciferase activity was measured and normalized by Renilla luciferase activity. Data are shown as mean ± S.D. (n = 6) of one representative experiment (⁄⁄p < 0.01).
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iﬁcity of IRF3 binding. All together, these EMSA data indicate that
LY294002 inhibits LPS- and poly(I:C)-induced IFN-b production
through inhibition of IRF3 activation and binding to IFN-b
promoter.
4. Discussion
In this report, we demonstrated that LY294002, a PI3K inhibitor,
inhibits LPS- and poly(I:C) induced IFN-b expression by inhibition
of IRF3 activation. Similarly, LY303511, an inactive analogue of
LY294002 that could not inhibit PI3K activation, also inhibited
LPS- and poly(I:C) induced IFN-b expression. In contrast, another
PI3K inhibitor wortmannin could not inhibit LPS- and poly(I:C) in-
duced IFN-b secretion and IFN-beta mRNA expression. In the case
of LPS stimulation, wortmannin even greatly enhanced IFN-b pro-
duction. Our data suggest that LY294002 inhibits IFN-b expression
independent of PI3K.Aksoy et al. reported that treatment with wortmannin or
LY294002 enhanced poly(I:C)-induced IFN-b production in mono-
cyte-derived dendritic cells [17]. The authors concluded that PI3K
negatively regulates LPS- and poly(I:C)-induced IFN-b production.
Consistent with these ﬁndings, we found wortmannin treatment
greatly increased IFN-b production in LPS-stimulated primary mac-
rophages. In contrast, we found LY294002 treatment attenuated
both LPS- and poly(I:C)-induced IFN-b production. The different
ﬁndings may be caused by the different cells (macrophage vs den-
dritic cell) and/or different species (mouse vs human). In agreement
with our ﬁndings, several reports have conﬁrmed LY294002 and
wortmannin have opposite functions to regulate gene expression
in RAW264.7 macrophages. For example, Kim et al. reported
LY294002 inhibits LPS-inducedNOproduction in RAW264.7macro-
phages [10]. Hazeki et al. also reported LY294002 strongly sup-
pressed TLR2/3/4/9 induced production of iNOS and cytokines in
RAW264.7 macrophages [18]. Recently, Avni et al. reported that
LY294002 inhibited LPS-induced IL-10 expression by RAW264.7
Fig. 5. LY294002 inhibits IRF3 transcriptional activation and binding to IFN-b promoter. (A) HEK293-TLR3 cells in 96-well plates (3  104/well) were transiently transfected
with 100 ng IRF3 reporter plasmid and 10 ng pTK-Renilla plasmid. After 24 h, cells were pretreated with DMSO, 25 lM LY294002 or 25 lM LY303511 and then stimulated
with 20 lg/ml poly(I:C) for 6 h. Luciferase activity was measured and normalized by Renilla luciferase activity. Data are shown as mean ± SD (n = 6) of one representative
experiment (⁄⁄p < 0.01). (B) Mouse peritoneal macrophages were pretreated with DMSO, 25 lM LY294002, 25 lM LY303511 or 1 lMwortmannin for 40 min, and stimulated
with poly (I:C) for 1 h. Then, nuclear extracts were prepared and EMSA was performed with the biotin-labeled IRF3 oligonucleotides from IFN-b promoter. (C) In competitive
binding assays, noncompetitive binding assays and supershift assays, unlabeled IRF3 oligonucleotides, unlabeled EBNA oligonucleotides and IRF3 antibody were added to the
above reactions with nuclear extracts from poly(I:C)-stimulated cells in the absence of PI3K inhibitors. Similar results were obtained in three independent experiments.
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LY294002 inhibits gene expression through a PI3K-independent
mechanism and another commonly used PI3K inhibitor wortman-
nin could not inhibit the expression of these genes, and in some
cases could enhance gene expression.
The signal pathways for the inhibitory effect of LY294002 on
gene expression are not fully understood. LPS- and poly(I:C)-in-
duced IFN-b expression mainly depends on the activation of tran-
scription factor IRF3. Upon stimulation, IRF3 was phosphorylated,
resulting in IRF3 dimerization and subsequent nuclear transloca-
tion and binding to IFN-b promoter. We demonstrated that
LY294002 targets molecules downstream of TBK1 to inhibit IFN-b
promoter activation. Furthermore, we found LY294002 treatment
greatly attenuated IRF3 transcriptional activation. Consistently,
IRF3 DNA binding to the IFN-b promoter was inhibited by
LY294002. Similarly, LY294002 has been reported to attenuate
NF-jB activation to repress LPS-induced NO production and IL-10
expression in RAW264.7 macrophages [10,19]. In this case, NF-
jB-binding to the iNOS promoter was greatly reduced as measured
by EMSA [10]. The ﬁnal step for activation of IRF3 and NF-jB is the
nuclear translocation and binding to target genes. LY294002 have
shown to inhibit potassium channels and calcium channels
[20,21], which may have an effect in the nuclear translocation of
these transcription factors. Indeed, Avni et al. has reported
LY294002 could inhibit p50 nuclear transloction to inhibit LPS-in-
duced IL-10 expression [19]. Thus, inhibition of nuclear transloca-
tion of transcription factors activation may represent a novel
mechanism used by LY294002 to repress gene expression.
In conclusion, our study has demonstrated a novel function for
the PI3K inhibitor LY294002 in the regulation of TLR-induced IFN-bproduction. LY294002 represses LPS- and poly(I:C)-induced IFN-b
expression through inhibiting IRF3 activation and DNA binding to
the IFN-b promoter in a PI3K-independent manner. Given the path-
ological role of IFN-b in autoimmune diseases, LY294002 may have
therapeutic potential to treat autoimmune diseases with uncon-
trolled IFN-b production.Acknowledgements
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